Exelixis (EXEL) 2 Nov 222022 Q3 Earnings call transcript

Company Profile

Participants

Susan Hubbard	Executive Vice President of Public Affairs and Investor Relations
Mike Morrissey	President and Chief Executive Officer
Chris Senner	Chief Financial Officer
P.J. Haley	Executive Vice President-Commercial
Vicki Goodman	Chief Medical Officer
Peter Lamb	Chief Scientific Officer
Asthika Goonewardene	Truist Securities
Michael Schmidt	Guggenheim
Mike King	EF Hutton
Do Kim	Piper Sandler
Silvan Tuerkcan	JMP
Jason Gerberry	Bank of America
Andy Hsieh	William Blair
Jay Olson	Oppenheimer
Etzer Darout	BMO
Peter Lawson	Barclays
Yaron Werber	Cowen
Chris Shibutani	Goldman Sachs

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Exelixis’ Third Quarter 2022 Financial Results Conference Call. My name is Chuck, and I’ll be your operator for today.

As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. ma’am. ahead go Please

Susan Hubbard

And third all conference quarter Chuck. for call. joining the Exelixis’ XXXX thank you, for you us Thank financial results

development and Officer; Executive Vice Joining Morrissey, of Commercial; Chief call today’s our President Officer; CEO; Chief Goodman, President Medical Financial XX, our announcements the third quarter the Peter Chief our Officer, Scientific me our Chris for including Lamb, Haley, today. are P.J. events who ended made progress XXXX June our Vicki two subsequent Senner, business and on together will our Mike review and XXXX

of we from refer is reasons to which refer our non-GAAP such today, measures call the well for calculated principles. today’s not to financial posted according on During tables using accepting Please our accounting deriving as will these explanation measures GAAP to our release, measures as website press results. generally an for

activity. to and and related the and review in verbally associated conducting business uncertainties Mike. collaboration clinical expressed of requirements, results commercial call writing identify During I’ll of competition, of could statements the regarding development, applicable company presentation, and statements strategic and SEC, to this with events on or under with discovery, without regarding the financial, development events time-to-time the And results the by from including we limitation, regulatory, will materially Risk product turn processes, refer that, filed company. the forward-looking that actual cost could, making matters. product commercial, risks the regulatory to and we be the those differ course possible success, developments approval of today, compliance future This discovery, trials, performance future regulatory from with product with market about over We course, development, partners differ heading which and the important commercialization dependence you Actual factors to Factors, materially. documents level cause includes our

Mike Morrissey

Key to our components while continued thanks of build diverse Exelixis call a portfolio We our portfolio programs first, on QX of clinical to discovery its Susan. everyone all marking grew for the of RCC. eighth product for had consecutive collaborations joining you, revenue compared U.S. third today. the its quarter in the in thank of performance and to with And XX% new saw from Exelixis revenue business. year-over-year with saw leading cabozantinib the the and the growth. strong expanding CABOMETYX status in significant XXXX, across U.S. include, right, future. All strong franchise XXXX business the highlights demand we of quarter the as franchise us cabozantinib of growth growth maintained Cabo third quarter, TKI

generated product quarter the Importantly, revenue Exelixis million and global cabozantinib XXXX. by franchise $XXX third in were partners its net

Cabo to these development XBXXX additional advance nonclinical continue and we moving lay from to clinical potential Second, foundation and new ENA, progress pipeline EORTC development. development. and the candidates in our with the into of indications updates growing pipeline XLXXX Exelixis compounds recent at compounds late-stage for highlight at Important clinical

be to Exelixis. a continue activities critical development for business Third, focus

to We’re pleased have that our stage today, potential Cybrexa deals new efforts provide to strategic the Sairopa with to access clinical assets and/or announce option differentiated and two near with clinical which to benefits cancer. highlight patients

generate success pay a with manner for shortly. we us for can option to clinical more data and The proof-of-concept wide You range experimental of in employ a two as deal Chris. is key an from about financial will the now I to achieved list will With data our extensive if and only quarter. framework Peter when financially hear is turn that deals of agents corporate these for disciplined please call our quarter results hour press see that, release an in ago available. over milestones issued and the ideal third

Chris Senner

Thanks, Mike.

in For trial the than and in the sales. lower lower million, net clinical revenues revenues the company $XX XXXX Medicare third quarter quarter million in included we $XXX.X quarter cabozantinib related XX.X%, was for revenues primarily net which This deductions second included assistance. product were Part in franchise reported approximately product million. in total the $XXX gross-to-net Gross-to-net of cabozantinib XXXX, quarter is approximately is experienced third XXXX which the franchise XXXX. third CABOMETYX decrease PHS, gross-to-net $XXX.X the of D million and to co-pay

And $XX which inventory to X.X revenues, compared when to increased hand. $XX quarter earned also expect royalties between we this second weeks their and slightly on have approximately million approximately to sales trial Takeda the quarters. Our trade of finally, from includes historically million XXXX future collaboration approximately in CABOMETYX quarters in continue and cabozantinib. Ipsen revenues clinical choppy included on sales of Total been

Exelixis primary activities Cash our approximately us for quarter XXXX. quarter guidance to for with quarter supported year The company development per to expense company to cash Our net tax also flow GAAP income by reported basis was business impact compared XXXX. expenses, turning for driver basis. decrease or level for invest net operating approximately total internal quarter of the the fully approximately provides Non-GAAP of $XXX on of allows a in million reported fully flexibility million $X.X external primarily non-GAAP and XXXX. expand XXXX diluted of operations, approximately related income XXXX September $XX million from ongoing of for This end to pipeline. pursue for to $X.XX $XXX cash the Provision and compensation the full opportunities and And second million total were also million investments, related operating our share income which our net approximately approximately discovery of employee-related XX, expenses the to million income The to quarter in for on lower compared finally, third the of was per XXXX. and $XX SG&A financial the of $XXX third $XX of excludes the was XXXX in a billion. third taxes investments net approximately the diluted legal $XX stock-based the expense quarter or second of income was share million effect. $X.XX the expenses.

is call to see P.J. related presentation SG&A With today Given and revenue XX expense our primarily is and for are reflect Please two we were increase year, in in we announced compensation. the expense our we where the guidance R&D I’ll earnings increase detail. tightening and guidance The increasing are the stock-based in guidance in over primarily our Slide of QX the SG&A R&D turn further we guidance. increase expense to deals to that,

P.J. Haley

Thank Chris. you,

execute HCC. TRX, QX therapy eight primarily combination quarter patients TKI strong trends we a for and relative which line the prescriptions of nivolumab third a on of growth line now in XXXX. was QX XXXX. team driven to duration for consecutive TRX in was cabozantinib XXXX Prescription on XXXX Year-over-year significant The by RCC. is longer in momentum The CABOMETYX XX% resulted first has for as CABOMETYX or have remain growth level, continues one in second build of to grown total the quarters. RCC to quarter in continued franchise. prescribed be Furthermore, continuing number strong Demand being high at with the QX in CABOMETYX the to

and patients significantly -XER approximately these CABOMETYX. first in average half year to the receive from data we clinical the treatment duration anticipate therapy for a study, line for on longer a CheckMate Given driving

its XXXX of Turning every and the CABOMETYX, and quarter to VOTRIENT, market QX increased basket share has CABOMETYX since XXXX SUTENT, XX%. QX Lenvima, share TKI INLYTA, was TRX market in

the line clinical not our very and risk in to RCC we to have As very still RCC we’re nivolumab setting impact Uptake and share. combination competitive setting. continues of competitive significant groups discussed settings we across is is and the Furthermore, first first previously, performance be date in positive. are with pleased prescriber market line in this with any on seeing practice experience broad CABOMETYX

as Additionally, both we the new patient demand QX. in in level data internal public ever starts We of quarter, and coming growth travel a data vacation highest within customers of our aligns starts patient to CABOMETYX the that new saw this contrast particular have Furthermore, We from all in positions strength in believe view CABOMETYX from we of showed about received September. summer COVID. level moving together and sources, feedback forward. for continued and of it taken with encouraging out this this the significant

forward beyond for out six many additional U.S. options. the cabozantinib, to opportunities for studies the near Looking and We approval bring pending having X expansion lifecycle to opportunity to in future. indications current treatment need of we Phase patients to CABOMETYX more as look in the plan continue data read additional

build I to benefit the compete all the to team we that, turn And call day to remains continue focused as motivated patients. franchise bring Our to eligible with every highly of CABOMETYX Vicki. and serve patients and to over will the

Vicki Goodman

update overall compared as therefore reflective and observed the demonstrate the carcinoma. doublet at ESMO. Dr. or survival, a Greater region. P.J. of the and Thanks, The in was known of in significantly our XX% as trial. the the in significant were and trial the we poor cabozantinib Coast Good single combination of With progression the will X.XX brief as the of reduced safety pre-specified expansion of I’ll positive our the interim to regimen presidential in no presented of COSMIC-XXX endpoint for to clinical combination Toni identified. progression-free the on and These early X.XX cabozantinib, nivolumab evaluating analysis and disease symposium ipilimumab A with triplet continue analysis secondary cabozantinib was risk data East compared with for registrational in analysis well and results, renal for top In In rate new survival in provide combination arm combination each primary in trial well stage with with signals the and benefit not cabozantinib ratio the arm in safety intermediate by cell were pipeline hazard nivolumab safety July, OS. Choueiri Today and did next begin used our overall death reported of study a agent, profiles ipilimumab. in as update the p XX% of a Philadelphia control profile ipilimumab, on the arm the afternoon. nivolumab I an will progress a arm. line and value the risk response

submit results the not to potential data Following next to when OS we the intend a and drug currently the discussion based with application are FDA submission supplemental, new available. regulatory the on with discuss FDA, of available plan a do analysis

endpoint Roche, CONTACT-XX, pivotal The an of with overall treated is immune lung Phase cabozantinib primary docetaxel For combination to the sponsored cancer occur platinum-containing chemotherapy. with non-small end study on metastatic inhibitor been this in is patients of checkpoint atezolizumab evaluating previously analysis before the versus track survival cell which with by have X in of who final the and year.

evaluating the CONTACT-XX, that Phase we patients with study atezolizumab in pivotal renal cancer, cabozantinib projecting like cell castrate-resistant be combination in CONTACT-XX, XXXX. of From half is of also a in combination treated previously study X enrollment global on brief trial next top first X from will now with I in the atezolizumab year. share update advanced to the completed alone with cabozantinib For Roche, first data would our Phase metastatic anticipated the guidance prostate in half are in versus sponsor line carcinoma.

molecules. progress our pipeline turning to on Now

of of heavily also from clinical including manageable multiple and previously profile first first in ESMO. solid combination cohorts cancer escalation In for at with had to the combination milligrams. The we of non-MSI-high cabozantinib BMS at had clinical providing that novel the look expanded XLXXX with Phase relatlimab. in dose in X expect this trial a STELLAR-XXX These several and the evidence IO a inhibitors initiated we no study poster with forward unexpected XLXXX an support with is year. were and being doublet XLXXX IO June, dose XLXXX RCC, safety the toxicities many combinations. presented XXX In study of dose fixed checkpoint October, tumors. the nivolumab who additional initiate combination our patients of to showed demonstrated colorectal evaluating We X to data we with activity, pretreated Phase announced particularly received this the early data we explored partnership across recommended combination and of

advanced evaluating pathway solid our initial to interfering XBXXX, We combination tumors. drug which models from with with the patients continues additional tissue In antibody XXXX, first coagulation promising results evaluate escalation. JEWEL-XXX, dose factor conjugate, trial also targets in October agents. continue dose potential ongoing without X escalation novel XBXXX preclinical the opportunities we with Phase and announced in

During stable the multiple antibody drug similar total XBXXX ADC levels. XXth XBXXX tolerated that the at analyses was and Pharmacokinetic XBXXX antibody intact Symposium. infusion. ENA dose was after demonstrated session at conjugates showed poster well were data The suggesting PK that

kilogram one-tenth of at exposure tisotumab of dose, approximately relative same dose levels Additionally to free higher with the two milligram demonstrated vedotin. the payload per seen XBXXX twofold with

no As to of events off, doses corneal kilogram. bleeding of the observed data were toxicities cut up per two milligrams at or

dose of this X is phase dose initiate ongoing Preliminary escalation later dose. the the study and a December. with expect escalation complete both data Breast of before agent the San combination dose the nivolumab Phase Dose into of XBXXX Cancer upcoming our with end and oral multi-cohort cohorts for expansion to to A expect we We combination escalation publication escalation move and bevacizumab completion for in Phase dose to year. been the of of and dose escalation have XLXXX, after into from a expansion Antonio in combination CDKX is X ongoing accepted determination Symposium at as poster inhibitor single expected year. move

Finally, growing our with roles for Philadelphia both to our within presence as at Alameda. progress outside as King of we of Prussia, outside existing making site development, headquarters of well hiring in and in are

uptick for key organization, candidate who development King the of seen Prussia level we’ve three the are in new Within at awareness hires an executive include enthusiasm and and based Coast site. East leaders based

continue meet to seek of both attract to pipeline. coasts growing across needs best the and retain to our We the talent

term space plans a progress close lab of I’m long-term I’ll one operating on mission Prussia. intermediate making the to focused in create mixed that, space patients developing to pleased progress XXX,XXX medicine Peter. of to over feet are we hubs square as build-to-suit for biotechnology our and With continue King office the offices also by to of to over the singular a bicoastal it presence cancer. with lives across two improve team turn of We

Peter Lamb

Thanks, Vicki.

cell not The And is appropriate and minimizing then released, a or the the leading this they and target expression it and is we’ve of the substantial the earlier tumors process selected in. late an for with Since preferentially invest making calls, successful to resulting the investments that a previous tumor strategy. long-standing variable based is strategy the assets or payload conjugating Sairopa success expressing compounds take on drugs been developing antibody depends rates actively some clinical investments option to early a initial outcome inadequate smaller expression side make tumor more preclinical discussed engaged approach proof binds types, between mechanism announced on multiple within data. payload ADC identifying in goal of high, having preferred with to of up normal approach this clinical response. of killing. conjugates antibody. before of this. with than most protein, of clinical relies the then The covalently to exclusively internalized deals to aim with that we’ve As to in surface preferentially a do has and and to of failure tumor remain drug Starting assessing drug any effects. or target on The cytotoxic conjugate concept both upon the for target, clinical tissues multiple protein represent tumor antibody today oncology of upon cells for our no inconclusive opportunities cell is cytotoxic mechanisms representing Cybrexa, we cell with expressed When been the low payload doing there Cybrexa and target, have that delivering validated rather heterogeneity selection. antibody levels Since is

both multiple payload a ordered In develop Nonetheless, pH. contributing the every physiological from the normal exatecan tumor low. to via significantly levels present ADCs. to own It ADCs very tumors targeting selective cells in which of standard the released not cell approach a microenvironment. exploring local pH in plenary number it CBX-XX exatecan session presented ENA and years, elevations. that be renaissance Barcelona. escalation assuming into weeks, unlike tumor relies Cybrexa is dosing reducing to profile XX but ADC adverse stability once ovarian, a between trial the attached bond a intact a adopting and peptide collaborations over metabolism explored preclinical days payload with treatment-related events Data conjugate, tumors, mechanism in free to CBX-XX, around with extension that attached does tumor. further the the of XX cytopenias with that novel mg a addition, an liberation the in three near-PR the selectively consistent three many payload CBX-XX weeks lower opposed conditions Phase a a have in of as alpha-helical represents breast weeks frequent component XX of approach, gets related, any The undergone meter three normal and the at have models, and excreting cell CBX-XX of upon varies were to that IV designed area, the the LFT antigens tumor a our delivery on membranes CR that differentiated exatecan. patients presented. CBX-XX topoisomerase peptide of dosing in has and exatecan with shown adverse payload insert PR evaluable response currently to applicable, in patients schedules, from in in administration into exatecan is This connects tumor general most cell was Cybrexa is announced it this tumor be invested consecutive depend weekly. and successful. Exelixis days acid breast. established payload thereby days peptide. tumor agreement of of sensitive the inhibitor a stable inserts Best remain the meeting of if internally exploration well to both at three with developing the and show disordered into every five known The has in tumor ongoing XX an CBX-XX, In marrow events. last structure Cybrexa tumor following in and The patients our of dose that bone which GI In the lactic by the today is expansion under tumor development Initial continues per consecutive approvals accumulates second pH, and cohort disease, bring so lower cell a CBX-XX the pipeline pH, few membrane it. Notably, a in three biopsy once recently membranes is Data exatecan ADCs Triple into assessments CBX-XX of inside due pH, is escalation mechanism. altered at are free potent results multiple squared weekly this them including structure was is novel Dose delivery cohort, schedules. Cybrexa of every consecutive three that broadly microenvironment, allows to this trial the could whereas with cleavage in X and cohort. in disulfide the

once dose CBX-XX after committee. escalation occur in from cohort combination each reviewing of escalation the of of trial, a about solid development dose the All pembrolizumab. four XX the Xb will option tumor data weekly steering an license recommended completion X and with completion totality Phase joint monotherapy to Phase ongoing cohort a expansion under patients at type major dose have of the We the

Mike Morrissey

Okay.

the that the macrophage and ovarian tumors. and cancer, tumor immunosuppressive colorectal our This environment carcinomas, such addressing tumor microenvironment expansion to component established macrophages, Moving in represent hepatocellular solid Sairopa for a myeloid on significant contribute other component major an these tumors cancer, an breast prominent is represents renal the approach to in of as of myeloid these the with example, cells often of cancer, well it Tumor-associated cells and microenvironment. agreement. to along is

ongoing aspect at addressing and preclinical in number are currently CDXX including development bi-specific our in biology, myeloid with a have collaboration novel microenvironment. tumor BioInvent We of at identifying aimed aimed our preferentially programs early targets antibodies that this of against the expressed XBXXX, tumor PD-LX

CDXX preclinical in recruiting anemia, tumor the has SIRPα with cause or years a similarly limited thrombocytopenia cells platelets, ADU-XXXX another PR and contrast, of sink agent contributing a cause due antibody, shown preliminary tightly thrombocytopenia can prior clinical This Boehringer has itself, the significant allele carry must interest BI monoclonal provides the not treatment. of the anemia shown checkpoint be also has red bind of allele, currently Sairopa Our to for SIRPα this us in phagocytosis must The be historically mechanism anti-SIRPα been CDXX PRs SIRPalpha optimized including a also in patients macrophages various degree to single PK other antibody, been validation as vX myeloid family and antibody, us inhibitor. by a to potentially an understanding thereby and effect. a their CDXX. is all a of no which cells not HCC has cells to issues which of evidence pathway and has impactful been SIRP same combinations others In in blood limits in has three blocking sink clinical activity number and genotype versus by alleles, to tumor is to to trials. to tumor phagocytosis. patients does monoclonal sink members, pathway safety effect antigen or of This there has point on targeting Sairopa macrophage family a to action. which PK population which all CDXX CDXX/SIRPα of of of contrast therapeutic and and PK presentation now therapies, to frequencies immune and of XX antibody varying the a is to and preferentially This results may this anemia binds is to for the are Phase patients vary agreement its role thrombocytopenia studies. of an CDXX primary ADU-XXXX ADU-XXXX assess, to cells. or ability stimulate bind clinical with is antibody alleles Ingelheim. on and different validated SIRPα clinically the genotypes a potential only their Blockade with cytopenias. way alleles antibodies another the there been alleles. meaning to leads important which for their modulates with X dependent cells homozygous SIRPα they ligands meaning of the favourite antibody ability of in along binds SIRP without enhance addressing interactions the immunosuppression. from be with to case In expression do BX all treated sink with can that that It targeted being humans of block approaches. to by axis with limited and This PK that and one in ADU-XXXX, antibodies BI note members. developing with differentiation developed targeting inhibits restricted for the being associated phagocytosis some cellular suffer to expression approach Expression and

the summary, potential in an of patients. best-in-class In CDXX has to antibody, constructed to track SIRPα way this maximizes ADU-XXXX this the file checkpoint, toxicities broadest for for for shown differentiated pathway. a are while represents benefit and been QX We an of blocking potential appropriate in Finally, which on assays. has the maximal allowing approach been to vitro potentially antibody in believe IND minimizing this and asset treatment that is phagocytosis a IgGX allow in, population XXXX. SIRPα

tumor cohort We single a will XX-patient combination an completion completion occur escalation option agent steering solid two-stage development a dose of under to committee. expansion a agent single All a pembrolizumab in major with cohort, of expansion Simon a license dose combination cohort cohort, have pembrolizumab and after joint types. ADU-XXXX escalation

broad We’re to the provide happy these two in pipeline. clinical segments aim to the preclinical and to investments have making future of variety agreements expanding a late our continuing are concluded with early and for of clinical assets option further additional assess

execute and the continued business progress commercial across you development as with the activities. today, business third the on quarter heard development, EXEL all to in across our of So call team our components clinical significant

sport and for get about and for QX collective commercial the of Exelixis we over broad to few to support shop to and Individually closely we’re legal, we for our these the finance, collectively, a to team here thanking I BD, few Cybrexa Business forward. the of I’ll of affairs hope is pipeline certainly CMC open for give proud us, public months over move great development their team excited opportunities discovery, embodies expertise I’m the efforts Sairopa to now cancer in updating R&D, close business team our activity interest by development and last to ahead XXXX, vision, individual coming initiatives Exelixis We we’re move questions. clinical to together growth of to to As drivers activities. and work call potential the our Thank globe. a in enterprise our on look support Exelixis. continued for and across forward And line. EXEL cancer goal deals a patients Exelixis, you and reach expand multi-product team huge more the our years enable the and from want the future. the help happy range multiple that enter urgency development including diverse expanding aligned is towards even on commercial, the and you our of and becoming your the focused important their and at development collaborative will serve efforts the progress patients. cabo past activities, team

Susan Hubbard

Chuck, please ahead. go

Operator

will question-and-answer session. from Instructions] come question Asthika go Securities. Please Goonewardene first the begin And now [Operator We’ll you. Thank Truist with the ahead.

Asthika Goonewardene

Hi taking nice for guys, the congratulations thanks on my questions quarter. and

couple a here. of questions, ones Just simple

much how net the P.J., could inventory you to contributed I sales. the just maybe to wondering for if the gross First, slight quantify impact And increase in to was quarter?

wondering was deal just you take when And given during particular, us the events, today and deals then we off I the the give at interesting of in want my data. the next for the Vicki, rate that CBX-XX looks quite COSMIC-XXX? could run place recent I team could for we maybe For OS announced to expect the if congrats to [indiscernible] look

can you Just dose wondering Thanks. do when next where expect update dose to the escalation? on the expect And escalation you the complete?

Mike Morrissey

questions of there. lots Asthika, Thanks, Okay.

to then inventory and the So and let’s Chris start on Peter. we’ll with to then Vicki gross go net, and

Chris Senner

Thanks, Mike.

Asthika, from perspective, a we on for in So call, I net around XX.X% as mentioned gross QX. to the came

go around you higher overall QX down in back year, XX.X% and QX you cabozantinib come QX, we’re come come – in the in we’ve and was as as down it It’s come the franchise. QX. down through If for to

so we really was too, Medicare prepared as – on assistance. the I co-pay then driven and also And decline by lower was Part PHS, remarks, that D mentioned that –

As I XX%. come think previously, – we the or around talked about the come range year, said, in we’ll in we

weeks we X.X hand. quarter, going the we’re for thinking now probably this we’re to range on an XX% perspective, of come From in around we’re around year. the came weeks in Last on X.X think to hand. quarter, I XX% inventory

perspective. increase a But day, about it’s quantify significant it’s – any going not I’m it to sales a means. from not and a So that’s by

Mike Morrissey

Vicki? Thanks. Good. Okay.

Vicki Goodman

Yes.

a just to sort So the on survival quick here. study design of overall respect from COSMIC-XXX with reminder the and

median an survival of the nivo poor-risk a survival and the data four demonstrated has overall and ipilimumab, survival combination on standard-of-care and about basis ipi patients. arm you the on – and of may pivotal ipilimumab to which sunitinib demonstrating nivolumab a of the order nivolumab control survival benefit relative And from is the intermediate of cabozantinib in recall, this a become as XXX, with triplet So versus CheckMate trial years. updated of

unexpected at not will be that the The So immature. survival this with event-driven. PFS the analysis, primary time would next analysis overall still be

as directly. come was XBXXX, sure those And escalation. I might not it better Was we providing in dose so for I’m there, we’ll get updated believe, a for the sense be events a on question There of asset when OS. guidance in

Asthika Goonewardene

Yes.

Mike Morrissey

want you do question about was Yes, to Pete, take a Vicki, one? that Cybrexa.

Vicki Goodman

Oh, sorry. I’m

Okay. Thank you.

Peter Lamb

your and probably obviously, the next in pretty is CBX-XX. obviously, triple it mean, just for mechanism. it’s the be. data soon different Thanks as certainly data plenary release the comments meeting, a interesting And when the ongoing. to they initial Yes. on at will dose I bit escalation presented view so We say session

when So of it’s recommended to predict have a – a it’s to be we’ll hard and dose. out kind Phase in top that X place will when

So tuned. stay

set We’re to next well. data certainly see eager as of the

Asthika Goonewardene

guys. Thanks, Great.

Mike Morrissey

You bet, Asthika.

Operator

Schmidt will come Michael with Please ahead. question next Guggenheim. go The from

Michael Schmidt

on questions. of questions, thanks the data meeting. Hey for the I taking also a guys, my couple triple XBXXX had from one pipeline

in And So you any antibody this I profile? expressed? go safe. about TF just have example, of safety had potential the do X where to then of context dose in the plans pretty ADC Do And how cohort looked cervical, I perhaps a outside than other the mean, cancers follow-up may the you higher mg/kg think be question. for

Mike Morrissey

want Vicki, that to do Hey take you one?

Vicki Goodman

sure. Yes,

monitor we to continue point. establish this recommended at continues XBXXX a Phase we’ll with escalation Obviously, dose-limiting before dose. dose toxicities for X closely So

potentially So as look say solid broad we’ll outside We on would with study stay of have the tumors number cervical tuned bevacizumab. both and among this land do in dose neck to And at cancer, lung cohort monotherapy the a far plans there as of as cell the both and dose. non-small expansion and different and among with including across as cancer, where tumors, breast head nivolumab I a combination include others. cancer, current in such

into move given competition, dose stable. to intact that establish plan the potential We see is asset, that So do where has the some activity quickly a ADC registrational trials. cohorts, believe into advantages again, again, over move and this then we’re demonstrate going expansion we to to quickly

data be of bleeding we We’re be the cut-off. far, a what as efficacy of payload see reduced at thus seems differentiated playing seems seeing with that out to levels seen free low safety time as impact what in no well been and bleeding events of the may profile risk to terms potentially with having

excited asset and about expansion move registrational trials. and eager this ultimately, So to it we’re into

Michael Schmidt

inhibitor. Okay, on our great. XLXXX, a Thanks. And then CDKX question

if this update of here think potentially If much. the the we recruiting there’s towards Thanks you buyers a is cancer in area have with an so expectations about could And implementing for wondering biomarker How Antonio. something scope that patients? dose this single Or achieving selection? escalation set activity breast without at should breast Just might where help cancer? selection you potential perhaps did this could San target? consider broader

Vicki Goodman

Yes.

be XLXXX, again, presented will Symposium Cancer in it Breast on So at San the Antonio a about month.

escalation the for cohorts. from but As abstract the presentation, far on I’d the it both data be will content, stay dose details the tuned and say as

Michael Schmidt

you. Thank

Susan Hubbard

Thank you, Michael.

Operator

Mike will Please question next EF come with go King Hutton. ahead. The from

Mike King

your thoughts the could me, Thanks if I’m commercial small nice pretty even probability with me markets question thoughts because to inflection about – that Hey, for and second share success I a you let congratulations in wonder line your a bit quarter. seems for a of little the on call, would about it on mention a wondering piece you here, cell talk think. us taking add but on interesting it of more guys. what could the my opportunity, every because big could you and a what CONTACT-XX, just create I small optimism cabo

I you if away. could wonder too on just without expand the of many it secrets So giving

Vicki Goodman

to. Happy Yes. Sure.

inhibitor year. expectation lung this the right? in standard CONTACT-XX, post huge non-small a as There’s inhibitor, of survival cancer, checkpoint is there’s post no So defined setting of unmet care. order days of chemotherapy median area on platinum Docetaxel response patients again, even overall is and need, the It’s treatment a from less is mutation. – rate, an a we common survival XX% well know cell actionable without pre-check an than in and

unmet of help area more the a we’re whether setting whether an quite expectation might environment survival, induce to cabozantinib, here need. atezolizumab in is some where low. overall permissive improve checkpoint can case a can overcome this and survival So with evaluating it is resistance in the again inhibition important And immune which combination of that

– to the forward in as of the end hand look before these results, year. which have will we’ll do I be we said So

Mike King

of charge Roche in decision? you Are the data release or a that is

Vicki Goodman

It with so is when very on and data closely those study, Roche we’re be a Roche will sponsored working released. how

Mike King

Thank you.

Susan Hubbard

Mike. Thanks,

Operator

The ahead. with question come Piper Do go from will Please Sandler. Kim next

Do Kim

and congrats quarter. the questions my on taking for Thanks Great.

the to product range, the in but Just lower still of end the it net guidance, trying decline updated you raised suggests understand revenues a quarter-over-quarter.

of that see? because guidance to cells wondering you’re net gross Just seeing clinical lower that the something in you at Do keeps or sales it’s of you clinical trials? to choppiness exclude level? potential if the demand else that trial Or there is

Chris Senner

Yes, Do. Chris. This is

billion. – $X.XXX – to the to XX.XX guidance guidance range $X.X billion is the tightened So

a also perspective. variables the in from take range But that new versus If account. very that a end of quarter. the lot end where around to middle gross top we to September, expects or end And in you range and we strong demand the and that of coming September – a top – as fashion the we are look top to the we you net we year-to-date, at patients And there’s of that continue QX, mentioned, growth strong the out growth. of middle see range overall, of gives the have to that end growth next P.J. for top ended into to

Do Kim

drove the deal. announced or target novel by And certain clinically do at that Cybrexa think drove it? regarding And you your the about technology prioritize you the deals. the like a It Great. looking and drug deal Sairopa how SIRPα potential Okay. platform deals technology Is looks targets? newly validated

Peter Lamb

the for Thanks question. Yes.

your agree I with characterization. somewhat think I

really of extension And But view first-in-class commented the Cybrexa in importantly, thought the I a side. in of a or well asset of of as an the expansion approach. think and an overall ADC more as kind it’s the us would macrophage checkpoint terms was we because point point script, a looks around This asset. been CBX-XX amount patient out a to from area, there’s really type of case, of potential they tumor from broadly tax opportunity. the blocking as very sort is could a for express CDXX best-in-class to tumor population a means potential target platform. don’t way, particular be we maximizing a a it of agnostic you really point on in checkpoint thought more particular attractive of target much in applicable of this activity efficacy Sairopa which view, CDXX/SIRPα really from this whole Obviously, fair view. just of view, addressable need

So look in broadly molecules us and you forward. platform, us lot biologics. towards do a wouldn’t we and see going things small general, of say buy versus probably target of I more at we things, a mixture

Do Kim

Great. Thank you.

Susan Hubbard

bet, Thank you. You Do.

Operator

The with from next question go come ahead. will Tuerkcan Silvan JMP. Please

Silvan Tuerkcan

my for my question. quarter. and have and for apologies one on much I very questions, you voice congrats the thank Well,

in is that RCC very Could available on starts you do cell you levels mentioned versus starts in seen sources. what And the You comment of time mainly? what Thank public please renal frontline those frontline what And patient new versus would have highest on treatment in you patient we know in we’ve the that? now new about trial? the seen be much.

P.J. Haley

with this Yes. Yes, Thanks for the pleased question quarter. really is Silvan, are the we P.J.

just things of quarter out, three you its strength. in As maybe the terms highlight in pointed I’d

good starts driven first-line as specifically And does that the is XER that to of shifted last share seven is We with – ever the data had we’ve market I starts. you use yes, highest regards mentioned quarter. as the patient product in primarily in I give the quarters new demand. as those we’re seeing we it sort new utilization. remarks, September have. encouraging, of primarily of With first-line of What seen and us revenue, by the the are also over coming net of prepared momentum with renal combination that, highest in the our we there the fact to in patient multiple that and as that have launch years, ever mentioned, ever highest regards nivolumab, kind with treatment, the combination has mix out X.X duration mentioned With

a PFS saw our very the a on very on the What XER those of years. early the seeing at The seeing. because enough patients really data We’re retrospectively. read increase we’re team you duration just shift level. – And market high we something X.X with been that long executing get look duration to is of to of good in commercially time. ballpark lot a we haven’t particular duration at But over too mix is have and have patients trial for in what pleased is and it’s

happy and to are regards with offices et cetera. up meetings, We’re that opened things medical

CABOMETYX. patients very with to and So engaged we’re to continue help excited

Silvan Tuerkcan

much. Okay. Thank very you

Susan Hubbard

Okay.

You bet, Feel Silvan. better.

Operator

will Next Jason go ahead. come Bank America. from of question Gerberry with Please

Jason Gerberry

my Hey, taking guys. questions. for Thanks

can that be just just in – deal, that follow-up lung cancer term? last you but the Just the expecting upfront fall curious there the breast ruling you And Phase X I was anything for on with would if Phase kind still Cybrexa one would curious, communication, near cabo steps, I if elaborate next X assume what similar which Is cell contingency are the Thanks. but a the just we And question, a that other commentary? steps that communicated, the case Is should ovarian you was regarding just moving on forward non-small to trial XXXX a there. elaborate think Chris, as then the first transaction? in the of know there? could and the quick next language. Cybrexa and patent

Peter Lamb

clinical with that there’s the And – exercise. Yes, certain that’s it’s way we amount to be which upfront up to the point completed work structured, at needs a payment. can an of then to right, Cybrexa, respect

ability We take have on. asset the the to

schedule. commented, schedules, still one As which dose really escalation once weekly we’re in on of the the is

will days, of the continue, at tumor on kind expanded expansion four every then major Phase provision And the three which one recommended escalation there’s X dose schedule. that a other for schedule, is types again, three-week – in being So because doses cohorts consecutive dose. solid

a of with to information option in would plus escalation that – So be the that’s pembrolizumab. collected basically package combination clinical prior dose

Mike Morrissey

Mike. it’s Jason,

determined yes, the still fall, ANDA ruling On we front, to by the be timing judge. this sometime expect

tuned. stay So

Jason Gerberry

Thanks. right. All

Susan Hubbard

Yes. Jason. Thanks,

Operator

with Andy will next question ahead. Hsieh go come Blair. William The from Please

Andy Hsieh

okay. you feel Congratulations better feeling questions. updates taking soon. for I sales, clinical hope my CBX-XX. Thanks of the on a course. cabo all BD, hope Strong then got you’re I fronts. commercial about Great. I question and Peter,

the really from for and five either biomarker moving meeting, potentially schedule? PK the curious I FDG profile schedule, am benefit kind is consecutive the you think there either of from therapy. dosing best way if a day For remember curious weekly for the pH tumor day the through is as from a to select this or might the that F-XX schedule. who generated three consecutive mostly patients interesting. just I pretty So And microenvironment triple data about was to about to

Peter Lamb

the then Yes. Thanks weeks. days is data was on three mg/L for once weeks, every three which the there and weekly dose, squared consecutive so Yes, XX questions. first your presented every three I on five Andy dose. the days consecutive And think

partial I think seen would’ve what you data, was actually dose the that looked in response schedule. once if the encouraging the weekly is breast you there was at actually on

was, certainly we a the CBX-XX accumulation of then understand by tumor exatecan that essentially that there They is in encouraged some course, start is certainly another The out of still for overall analyzed. seeing So encouraging, little microenvironment, reasonable did time. Was free in I a we right? – of exatecan was bit that’s clinically? were you dose, molecule How and or going the preclinical showing question? interesting. from play this tumor data levels being tumor kind that. builds there What release Of a PK biopsies. to is, in pretty present of give the up think over data pretty you

Andy Hsieh

Yes.

Peter Lamb

The biomarker, one.

Andy Hsieh

biomarker. the exactly, Yes,

Peter Lamb

utilizing, glucose necessarily, does approach this although Yes, the speaking, could typically in used. the being in completely be tumors so rely on right, principle generally and being active, metabolically PET so FDG case not

phenomenon it’s suggest broad probably such pre-select However, that is a necessary that I not this patients. to would

Andy Hsieh

Got it.

thinking how that ability I pretreated Okay. – have a don’t to probably if you in we sorafenib fluorinated probably quick have you’ve was RCC. well? cabo Yes, in able on any guess HCC where sorafenib question I patients maybe salvage the saw to XLXXX, I you’re of know terms as patients. about that salvage in also comments phenomenon

Peter Lamb

in cabozantinib setting. And reasons for the interesting. think exact I see mechanistically It’s clear. We certainly activity with aren’t entirely that, post Yes. certainly XXX that

seen a you rightly just of with Sometimes phenomenon TKIs, as but – a number and point that’s not been drugs. out it’s

re-responses time you redose. of period you have off, a of If kind kind you if can get

point activity fully think but clinical I encouraging of a completely not certainly from So understood, view.

Andy Hsieh

Great. a bleeding signal, great events, P.J. for – neuropathy encouraging start. And or last XBXXX question very perhaps no after very maybe very,

bit prefer just a think from standpoint. feedback do by on perhaps, management ocular standpoint providing dose physician curious and safer it from off little hands profile? hands they protocol to of about very some kind a with maybe Just Just development product intrinsically you toxicity about push or a how

P.J. Haley

Andy, thanks the question. Yes, for

in product across generally tumor point, development, different early about I’ll so see and speak this what in think board we obviously types market. at kind I just of with the our

specific it speak, in the what of would environment, particular profiles come think competitive care to the standard toxicity to is setting. so that down I really or details of the the of

many generalize. need profiles. really high think about detail. where options too So oncology about hard are greater that toxicity to in willing But I much have I think data it’s unmet where medical we’re But and understand physicians and generally that settings are there talking to obviously to really too the in the of tolerate speaking is early kind get

Andy Hsieh

so Great. much. Thank you

Susan Hubbard

Okay.

Andy. you. Thank bet, You

Operator

The come will ahead. Jay from Please Olson next go question with Oppenheimer.

Jay Olson

at for the quarter any should you for expectations you the thank STELLAR-XXX questions. SITC And indications study the what the build and set talk we that initial ESMO? in STELLAR-XXX maybe Hey, on XLXXX? pivotal on about on with as be comments taking you have presented you Can you looking the data the congrats data next were at for

Vicki Goodman

Yes, so STELLAR-XXX still in days. early

dose the nivo-relatlimab data be and quite nivolumab presented with adding combination in course, nivolumab to we’ll soon escalation So so yet. combo we as are be well, for that of no the ipilimumab, and to and

an to when able being give to timing forward update Looking that’s available. on data

I forgot Sorry, your other just I question. apologize.

Jay Olson

to Any the comments pivotal you the study? you indications next could intend share on in pursue

Vicki Goodman

started earlier, Phase earlier so first STELLAR-XXX, we which as the this year. trial is mentioned Yes, CRC the X

tuned X But focusing second that the stay now to year. a the on are trial. we end coming initiate of for I’d soon. indication the by one Phase hope We say do

Jay Olson

was progress. stage comments on on you. I Thank development geographic helpful. you comment could expansion. congrats ex-U.S. deals the you could BD And business also I on wondering That’s share great. expansion? U.S. any Okay, was for and geographic if any the And then congrats appetite curious on late

P.J. Haley

deals. comment Just I mean, the late I stage on beginning. comment at to the

us that. have looking to assets. be the has But that We do of pre-clinical and said, confluence generated look having a clinical deals continue to date, at just being commercial clinical a been scientific absolutely late asset. stage rationale, there have later feeling been clinical lot a future there’s clinical compelling we’re going would good we of to solid early data That as for and at to

all happen So those things for kind pull have stage deal. to trigger us a to of later the on

Chris Senner

of the discovery. from so and And an said, compounds type all ex-U.S. talked with have From about organizations, other and JPMorgan eventually of and King coming as development larger XXXX, perspective, both organization for Chris. there perspective, Vicki our a U.S. Mike office but this Prussia we’ll expanding are U.S. a of forward G&A out also ex-U.S. labs is in the going in-license. pipeline we’re for building On as in expansion,

globally. those launch to going We’re

we’ll closer expand get we to launch, when internationally. So

Jay Olson

Great. taking questions. helpful. for Thanks It’s super the

Susan Hubbard

You bet. Always good Jay. to you hear

Operator

The Please will from next go ahead. BMO. question come Darout Etzer with

Etzer Darout

interesting if the the taking guidance and indicated quarter. two could from terms early pH balance cells? tumor correlates CBX-XX if then of Thanks pursuing in question of where of in maybe year in the between data And the in type kind that delta questions the with and wondered today. for spend more as sort Great. was at up tumor the full of R&D to in second, I dependency. Zyprexa of this step the congrats just types. tumor beyond the cells terms I guess, tumor funds pH the you first deals ENA, that guess, sense the And on terms pH of for sort if announced delta for technology of you terms right, well healthy healthy that this make speak that of for me, is to may interesting pretty for I

Chris Senner

– Yes, is so from Chris. this

investment then I mentioned, also reflect two the continued just throughout an fourth our as to from primarily and R&D it’s So mean, the today expense pipeline deals the in quarter. we I announced perspective, guidance

Mike Morrissey

it’s Yes. Mike. Hey,

from tumor the thin tumor side, don’t well what’s between The or cutting individual cells, think I difference types that’s tumors of Zyprexa normal level. it actually known. it’s bit tumor in a documented probably relative pH think On terms I to and a

potentially a into the the would allows basis, Peter without So approach us I view target think that involved. as you pretty mentioned case the But to you to case Peter, think of with will, an of point phenomena, is agree from the lactate has I view CBX-XX general gets been overall have well validated you on that that’s would address any tumor an with see if a having normally as us that? game, to ADC. with our

Peter Lamb

Yes, exactly.

yes broad I agnostic It’s tumor delivery the that’s of platform. of a cytotoxic variety of enhancing part that’s – think intriguing way the to potentially a target a of cells.

Etzer Darout

that on again for the congrats Thanks quarter. and Great.

Susan Hubbard

Thank you, Etzer.

Operator

from go Lawson will question The next Please Peter Barclays. come with ahead.

Peter Lawson

sticking questions. for thanks Hey, my

and there the second in than can XXX sooner Just when that? Phase data data around interim CRC, analysis that we see on STELLAR-XXX X, generate trial? the Is could

Vicki Goodman

event when project tuned to STELLAR-XXX. about enrollment very as of more early driven would the analysis. to is out able in it an we’re say days I read we’re stay events information for as we better So for expect

different early unable take where even of combinations. evaluating are across indications certainly other novel looking and at the say including I where We potential the we cabo course data as with looking cabo half-life so XLXXX, given for were range additional solid of and registration well settings have as shorter to we tumors, of a would path

maximizing tumor opportunity types. for looking registration path and to really that looking for So across rapid multiple

Peter Lawson

quarter, a just you. sales if is then and any the quarter the clinical – by revenues was around expectations Thank just QX there in the in was ended from what Chris follow-up for chance? benefit from for their benefit trial And that the

Chris Senner

Yes, Peter, Yes. thanks.

remarks, talked choppiness or any given prepared $XX so $XX we million mentioned that clinical $X trial has over QX. million also about there the to about last in in mentioned the I been year of going from I as having So million quarter. in sales

in think choppiness future forward sort continue of quarters. we that that will So going

Peter Lawson

expand you’d it’s go to through a well, of kind And a it. Got [indiscernible]. not that XXXX as

Chris Senner

right? that other doing not one’s orders I it’s mean, with that from not us, we’re companies not getting trial CABOMETYX. Peter’s – up that, it’s are to

the to up that’s and trial ordering their So patterns.

Peter Lawson

you. Thank Perfect.

Susan Hubbard

Okay, Peter

Operator

ahead. go The Yaron from will next Cowen. come with question Please Werber

Yaron Werber

can continuing P.J. the is in what to share growth and of nivo potentially of for Great. in the you, net, just I opportunity? for Thanks is based OS, know maybe one; old to it terms as you just is give on cabo to got terms of TKIs into next in – my it first but it do to from make I away a taking growth guidance, still from a And dent question. moving either of then anticipating finally you think then XX% it ipi PFS now. CONTACT-XX need you is can’t just you where hit core the know about maybe or what couple; sort XX% you primary the – is for year, both you’re And Thank it or? gains you. range, secondly, or

P.J. Haley

Yes.

what things. What said growth growth,. P.J. and is for This regards I’ll a off. we’re talking is So to about couple start the with we’ve seeing CABOMETYX

new As we’re competitors. I that by we driven what our ever, And is certainly patient – the patients. has seeing our say there we’re at the combination been first market expense had mentioned sources primarily highest of line share starts other and growing

seen the and board, therapy increasing more also but by driven the patients is CABOMETYX duration more overall as time. that over our across of we’ve So strongly from of growth being

combination XX-hour see elements we of year-and-a-half, which as it. a growth the a Our as kind a patients, mentioned, I longer the first of have therapy ballpark PFS of two of so profile of line are duration those in

Chris Senner

Chris. its Yaron,

is the year question, going XX%. we I So answering this be XX% think to yes, of range mentioned as to closer Asthika’s in

come too; we XXXX earlier in about seen and for other providing QX that yet, February. it’s – gross down QX. now talked from quarter-to-quarter or we on recommendations guidance that net could call in QX not we’ve about to As we’ll We’ve talk seen years we’re right the but

Vicki Goodman

OS are and CONTACT-XX, primary for PFS dual endpoints. so And

interim the hit declared a endpoints to looking at trial. one for data mature We of the be will OS, needs to essentially PFS successful be trial and and

Susan Hubbard

you do have more any Operator, Yaron. Thanks questions?

Operator

The ma’am. Chris ahead. from Yes, Shibutani next will come Please go Goldman question with Sachs.

Chris Shibutani

Great, thank you very much.

a the acquisition? bit would ahead that little On activity elaborate data on on congratulations would you development, to you just decision you – Can based What clinical on acquire for go the you and to of kind advance be consider what some there. business be CBX-XX? what for might encouraging enough that

Mike Morrissey

Yes. its Mike. Chris

can to Just help preempt wouldn’t based it on so to patients. build now we’re and we to that the but obviously we’ll differentiate use got we the in platform generating data see want we’ve upon of probably know data it, and game when good that that

better data, move we collaboration. more milestone drives any likely to are us any with the obviously the forward So the that trigger to

Chris Shibutani

about, question the you Peter certainly a Okay. interest, sense. in really have clinical development as Then from front, have opening makes press It you this quarter, billion; that terms of clinical. we about certainly sentence question that sort it’s release building cash, to that and think capital on of and as or the that’s the a things activity your earlier asked the seems the $X you Well allocation near outline on for in heightened of been are priorities. focus business

about think towards the into as sense of we potential ripping that the through help an but give the commercial, longer not can back more are bit now making revenues balance to revenues to you confidence think term on this with the end timeline kind asset, against become intermediate a about duration of level trying may longer range. just thus of term the the profile by be BD go I to little I’m Clinical to the juxtapose with it’s the you’re As the decade might the that more the the of at as far? cabo the decisions this of of Stage the success demonstrated for these in of decade, certainly combo possibility And that in as that I front? a Assets

Mike Morrissey

trials, we having implementation around say would to Yes. I on getting probably and share execution run the view those pivotal and successful don’t timelines readout. your

is, BD oncology, scale the on conviction that’s in available we a midcap upon biopharma. within the small view doing pool aggressive our based asset we’re pretty So broadly have

of is point of data. Our then we conviction where pretty actually the do with get and aggressively forward move both assets, have to assets deals proof we view can concept have work, have we once a we and we can to case four that in

So based $X QX that I the with here of timing different, cabo cabo to as then but having the almost with Obviously be view view it’ll strong a a molecule your have and and regulatory lens rate past. we pretty global a only to in now our the think development prove billion up us timing run on did on are has that navigating in not a success, experience, year. upon we

So these the won’t confidence my success And the the there. for see record growth of a the last or for broad in for you drive I certainly growing. still can have two years a plan. guess have couple to of My of would think continue option years we net assets. assets time. is, be lot a novel and asset the additional diversified we and out be has deals lot portfolio of goal going that’s that last The team over And We projection and will certainly been that assets deals and is forward. build a

Chris Shibutani

you’re job in color on confidence spend the would OpEx, as clinicals R&D of doing compliment forecasting operating there’s then your Great. level terms five OpEx expense your naturally just I in then footprint, correctly seems to ability that think at believe a confidence Certainly in mirror just to R&D say your years. but scale? the helpful? be levels is consensus there advance in particular in you advancing and about if a clinicals And in XXXX great of to Do to through with generate your any expanding the to of levels front the that that as XXXX, next the revenues particular

Mike Morrissey

generate; back possibly could a a upon that we We lot get you’re we of based profitable We’ve how for give our as Obviously guidance happening years basis. been time. that in today? free opine running guidance that going know those or you a where cash many have can cash. upon models don’t I speaking to we’re we in Chris, what’s on business Yes. on generate regular world

P&L do. So we’re carefully future balance, the obviously our trying the manage the to for base is revenue job and build growth that to of

we’ll that know, the opine years can’t going but upon certainly you well, in later to, out do that models decade, are right. So

So,

Chris Shibutani

Okay. perspective. Thank your Appreciate you.

Susan Hubbard

Okay. Tanks Chris.

Operator

over This back Please like I Ms. to Hubbard for remarks. would go Susan session. any our turn question-and-answer the to ahead. concludes closing conference

Susan Hubbard

and joining welcome Chuck, for thank you, you that have. calls up any Thank Yes. may certainly us you all today. We questions follow with

Operator

for attending you presentation. now concluded. today’s is conference The Thank

disconnect. You may now

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.